New vaccine aims to shield toddlers from 24 pneumonia strains

NCT ID NCT06800261

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sinovac Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new vaccine (PCV24) designed to protect children aged 2 to 23 months against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. Around 180 healthy children will receive either the new vaccine or an existing one to compare safety and immune response. The goal is to see if the vaccine is safe and triggers strong protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL INFECTIOUS DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shandong Provincial Center for Disease Control and Prevention
NOT_YET_RECRUITING

Jinan, Shandong, 250014, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shanxian Center for Disease Control and Prevention
RECRUITING

Shancheng, Shandong, 250014, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.